Predictors of resignation and sick leave after cancer diagnosis among Japanese breast cancer survivors: a cross-sectional study.
Breast cancer survivors
Resignation
Return to work
Sick leave
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
14 01 2021
14 01 2021
Historique:
received:
19
03
2020
accepted:
05
01
2021
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
In Japan, 55.5% of breast cancer survivors (BCSs) are of working age, so various perspectives regarding return to work (RTW) after cancer diagnosis need to be considered. Therefore, this study aimed to clarify the risk factors for resignation and taking sick leave (SL) among BCSs in continued employment at the time of diagnosis. A web-based retrospective cross-sectional survey was conducted on BCSs using data from a 2018 Japanese national research project (Endo-Han) commissioned by the Ministry of Health, Labour and Welfare of Japan. The subjects were women aged 18-69 years who had been diagnosed with breast cancer for the first time at least 1 year previously. The risk factors for resignation and taking SL after breast cancer diagnosis, including age at diagnosis, education level, cancer stage, surgery, chemotherapy, radiotherapy, employment status, and occupational type, were then analyzed using a logistic regression model. In total, 40 (14.9%) of 269 BCSs quit their jobs at least 1 year after being diagnosed with breast cancer. The results of the multivariable analysis indicated that lower education level (odds ratio [OR]: 3.802; 95% confidence interval [CI]: 1.233-11.729), taking SL (OR: 2.514; 95%CI: 1.202-5.261), and younger age at diagnosis (OR: 0.470; 95%CI: 0.221-0.998) were predictors of resignation. Of 229 patients who continued working, SL was taken by 72 (31.4%). In addition, undergoing surgery was found to be a predictor of taking SL (OR: 8.311; 95%CI: 1.007-68.621). In total, 40 (14.9%) of 269 BCSs quit their jobs at least 1 year after being diagnosed with breast cancer. The results of this study indicated that younger age, lower education level, and taking SL were predictors of resignation after breast cancer diagnosis.
Sections du résumé
BACKGROUND
In Japan, 55.5% of breast cancer survivors (BCSs) are of working age, so various perspectives regarding return to work (RTW) after cancer diagnosis need to be considered. Therefore, this study aimed to clarify the risk factors for resignation and taking sick leave (SL) among BCSs in continued employment at the time of diagnosis.
METHODS
A web-based retrospective cross-sectional survey was conducted on BCSs using data from a 2018 Japanese national research project (Endo-Han) commissioned by the Ministry of Health, Labour and Welfare of Japan. The subjects were women aged 18-69 years who had been diagnosed with breast cancer for the first time at least 1 year previously. The risk factors for resignation and taking SL after breast cancer diagnosis, including age at diagnosis, education level, cancer stage, surgery, chemotherapy, radiotherapy, employment status, and occupational type, were then analyzed using a logistic regression model.
RESULTS
In total, 40 (14.9%) of 269 BCSs quit their jobs at least 1 year after being diagnosed with breast cancer. The results of the multivariable analysis indicated that lower education level (odds ratio [OR]: 3.802; 95% confidence interval [CI]: 1.233-11.729), taking SL (OR: 2.514; 95%CI: 1.202-5.261), and younger age at diagnosis (OR: 0.470; 95%CI: 0.221-0.998) were predictors of resignation. Of 229 patients who continued working, SL was taken by 72 (31.4%). In addition, undergoing surgery was found to be a predictor of taking SL (OR: 8.311; 95%CI: 1.007-68.621).
CONCLUSIONS
In total, 40 (14.9%) of 269 BCSs quit their jobs at least 1 year after being diagnosed with breast cancer. The results of this study indicated that younger age, lower education level, and taking SL were predictors of resignation after breast cancer diagnosis.
Identifiants
pubmed: 33446165
doi: 10.1186/s12889-021-10168-2
pii: 10.1186/s12889-021-10168-2
pmc: PMC7809813
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
138Subventions
Organisme : Ministry of Health, Labour and Welfare
ID : Gan-taisaku-ippan-012
Références
J Cancer Surviv. 2007 Jun;1(2):129-36
pubmed: 18648953
Asia Pac J Oncol Nurs. 2017 Jan-Mar;4(1):6-17
pubmed: 28217724
J Epidemiol. 2018 Feb 5;28(2):88-93
pubmed: 29093353
J Clin Oncol. 2005 Nov 20;23(33):8305-12
pubmed: 16219927
Br J Cancer. 2016 Jan 12;114(1):81-7
pubmed: 26757424
Disabil Rehabil. 2018 Jun;40(13):1485-1493
pubmed: 28325132
Acta Oncol. 2007;46(4):417-32
pubmed: 17497308
Psychooncology. 2002 Mar-Apr;11(2):124-31
pubmed: 11921328
Jpn J Clin Oncol. 2011 Jan;41(1):40-51
pubmed: 20819833
Acta Oncol. 2007;46(4):446-51
pubmed: 17497311
Eur J Oncol Nurs. 2013 Feb;17(1):101-6
pubmed: 22705269
Psychooncology. 2013 May;22(5):1008-16
pubmed: 22678743
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13051
pubmed: 31033073
Breast Cancer Res Treat. 2013 Jul;140(2):407-16
pubmed: 23884596
Cancer. 2017 Dec 15;123(24):4791-4799
pubmed: 28990155
JAMA. 2009 Feb 18;301(7):753-62
pubmed: 19224752
J Cancer Surviv. 2016 Apr;10(2):320-9
pubmed: 26318185
Scand J Caring Sci. 2018 Jun;32(2):715-724
pubmed: 29048131
Eur J Cancer. 2008 Sep;44(13):1866-74
pubmed: 18640029
J Occup Health. 2014;56(1):49-55
pubmed: 24430841
Crit Rev Oncol Hematol. 2011 Feb;77(2):109-30
pubmed: 20117019
J Occup Rehabil. 2013 Sep;23(3):391-9
pubmed: 23179743
J Clin Oncol. 2018 Jun 20;36(18):1868-1879
pubmed: 29757686
Occup Environ Med. 2010 Sep;67(9):639-48
pubmed: 20798030
Breast. 2019 Apr;44:24-28
pubmed: 30597404
J Cancer Surviv. 2020 Apr;14(2):106-113
pubmed: 31721037
BMJ Open. 2018 May 18;8(5):e020276
pubmed: 29776920
J Cancer Surviv. 2018 Apr;12(2):169-177
pubmed: 29076003
J Occup Environ Med. 2011 Jun;53(6):674-9
pubmed: 21654440
Occup Med (Lond). 2009 Sep;59(6):373-7
pubmed: 19692522
Psychooncology. 2013 Jun;22(6):1411-20
pubmed: 22912069
Eur J Cancer Care (Engl). 2013 Mar;22(2):144-60
pubmed: 23279195
Iran Red Crescent Med J. 2015 Sep 22;17(9):e19978
pubmed: 26473073
Psychooncology. 2014 Jun;23(6):634-41
pubmed: 24347387
Ann Epidemiol. 2015 Nov;25(11):832-8
pubmed: 26320705
J Occup Rehabil. 2010 Mar;20(1):49-58
pubmed: 19902340
Jpn J Clin Oncol. 2018 Aug 1;48(8):712-717
pubmed: 29939297